However, the combination of both compounds resulted in 29–100% tumour cell killing in six out of seven MCT1+/MCT4− DLBCL lines, confirming that the simultaneous targeting of two key metabolic pathways can deliver a highly pronounced therapeutic effect. Here, SLC16A1 is linked to diffuse large B-cell lymphoma.